On December 14, we signed a framework agreement with the Gustave Roussy Institute for projects in oncology and immuno-oncology. This is a long-term strategic collaboration – four years renewable – which aims to optimize therapeutic management of several cancers.
Ranked as Europe’s leading oncology center and the third largest in the world, the Gustave Roussy Institute is a global center of expertise entirely dedicated to cancer patients. Based near Paris, it welcomes nearly 50,000 patients each year and develops an integrated approach between research, care and teaching.
To date, thanks to this partnership, five projects in adult and pediatric oncology have been identified and will be launched shortly. They concern indications of interest developed by Servier and which still have unmet needs. The agreement is also accompanied by early phase clinical trials with innovative compounds from Servier’s oncology pipeline that will be conducted by Gustave Roussy.
“This collaboration allows combining the expertise of Servier and Gustave Roussy, with the common objective of initiating ambitious R&D projects for purposes of developing therapeutic innovations targeting resistant cancers, such as certain acute myeloid leukemias in adults, and treatments targeting cancers with high unmet needs, such as certain brain tumors in children.”
Prof. Angelo Paci, Program Leader Oncology and Immuno-onco at Servier
“It is the culmination of a long-standing collaboration that will eventually be reflected in the Paris-Saclay Cancer Cluster. The first research projects in hematology, immuno-oncology and pediatrics illustrate the scope and momentum that this agreement will further boost our collaboration.”
Prof. Fabrice Barlesi, CEO of Gustave Roussy
Did you know?
We have made oncology one of our priorities, investing over half of our R&D budget to it. Our ambition is to become a renowned, focused and innovative player in cancer treatments.
This partnership illustrates Servier’s strong collaborative innovation drive to accelerate the discovery of first-in-class treatments for patients. The opening of our Servier Paris-Saclay R&D institute in the first half of 2023 will give a new dimension to this strategic partnership.
Discover our oncology pipeline (November 2022)